// App-Quantinova.ai

S299 : PHASE I/II UPDATED SAFETY AND EFFICACY RESULTS OF ORAL BRUTON TYROSINE KINASE (BTK) INHIBITOR RILZABRUTINIB IN RELAPSED/REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP)

Researchers

Presenter

  • David J. Kuter

Principal Investigators

  • Merlin Efraim

  • Zane Kaplan

  • Jiri Mayer

  • Philip Choi

  • A.J.Gerard Jansen

  • Vickie McDonald

  • Ross Baker

  • Robert Bird

  • Mamta Garg

  • Jaromir Gumulec

  • Milan Kostal

  • Terry Gernsheimer

  • Waleed Ghanima

  • Olga Bandman

  • Puneet Arora

  • Regan Burns

  • Hailing Guo

  • Fareha Iqbal

  • Dolca Thomas

  • Ann Neale

  • Quynh Tran

  • Nichola Cooper

Medical Centers

  • Multiprofile Hospital for Active Treatment Sv. Marina , Varna, Bulgaria

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom

  • Princess Alexandra Hospital, Woolloongabba, Australia

  • The Canberra Hospital, Canberra, Australia

  • Østfold Hospital Foundation,Gralum,Noruega

  • University of Washington Medical Center Seattle WA United States

  • Hematology Division,Massachusetts General Hospital, Harvard Medical School,Boston,United States

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • UMHAT Dr. Georgi Stranski, EAD, Pleven, Clinic of Hematology,Pleven,Bulgaria

  • Department of Haematooncology, University Hospital Ostrava and the Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

  • Monash Medical Centre, Australia

  • Perth Blood Institute, Murdoch University, Perth, Australia

  • Principia Biopharma Inc, a Sanofi Company,South San Francisco,United States

  • Fourth Department of Internal Medicine and Hematology, Faculty of Medicine, University Hospital of Hradec Kralove,Hradec Kralove,Tschechische Republik

  • Biostatistics, Sanofi US Services Inc.,Bridgewater,Estados Unidos

  • Department of Haematology,Guy's Hospital,London,United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

Locations

  • Bulgaria

  • Czech Republic

  • United Kingdom

  • Australia

  • Norway

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT03395210

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved